We use cookies for a better user experience. Read our Privacy Policy

I Agree

PET Radiotracer Market

PET Radiotracer Market (Product: F-18 [FDG18], Ga-68 [FAPI], and Others; and Application: Cancer, Heart Disease, Gastrointestinal, Endocrine, Neurological Disorders, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

PET Radiotracer Market Outlook 2031

  • The global PET radiotracer market was valued at US$ 1.4 Bn in 2021
  • The global market is projected to grow at a CAGR of 8.5% from 2022 to 2031
  • The global PET radiotracer market is anticipated to reach more than US$ 3.2 Bn by the end of 2031

Analysts’ Viewpoint on PET Radiotracer Market Scenario

PET radiotracer, also known as PET tracer, is a positron-emitting radiopharmaceutical used in positron emission tomography (PET). Increase in incidence of neurological, cancer, and cardiac diseases; rise in capability to produce PET scan radiotracers such as Fapi radiotracer and nuclear imaging in-house; and growth in preference for PET/CT and PET scans are the key factors anticipated to drive the market size for PET radiotracers. Key players are engaging in significant research & development activities to widen their product portfolios and thus broaden their revenue streams. For instance, on June 19, 2020, Lantheus Holdings, Inc. completed the acquisition of Progenics Pharmaceuticals, Inc., an oncology company focused on the development and commercialization of innovative targeted imaging agents.

Infograph_pet Radiotracer Market

PET Radiotracer Market Introduction

Radiotracers used in positron emission tomography (PET) are chemical compounds comprising more than one atom replaced by a radioisotope. Each tracer consists of a positron-emitting isotope (radioactive tag) bound to an organic ligand (targeting agent). PET radiotracers are administered intravenously. Radiotracers are used for tracking the mechanism of chemical reactions taking part in a biological system such as glucose metabolism, amino acid uptake, glucocorticoid synthesis, and other metabolic studies. Different types of radiotracers are used in PET for metabolic studies for visualization using PET imaging.

The International Atomic Energy Agency (IAEA) plays an important role in assisting the transfer of radiotracer technology to developing member states. Commonly used PET radiotracers for imaging are F 18 FDG, C-11 Methionine, F 18 fluoroethyl-l-tyrosine (FET), F 18 fluoro-dihydroxy-l-phenylalanine (F-DOPA), and C 11 Etomidate.

According to the American Nuclear Society, more than 10,000 hospitals throughout the world use radioisotopes. Nearly 90% of these are used for the diagnosis of infectious diseases, cancer, neurological disorders, and other diagnostic applications, allowing for cerebral blood flow visualization, tumor protein synthesis, neuroendocrine imaging, myocardial perfusion, and other studies.

Request a sample to get extensive insights into the PET Radiotracer Market

Increase in Incidence of Neurological, Cancer, and Cardiac Diseases to Propel Global PET Radiotracer Market

PET is an important molecular imaging technology utilized for the assessment of neurological disorders. According to World Health Organization’s (WHO) 2021 estimates, nearly 55 million people across the globe have dementia, with Alzheimer's disease being the most common cause accounting for 60% to 70% of all dementia diagnoses. PET scanners provide comprehensive visualization of neurological abnormalities including determination of the location of the epileptic seizures before surgery, diagnosis of movement disorders, and ability to identify and diagnose early stages of Alzheimer’s and other dementia. Diagnostic tracers for neurological indications have become a key area of interest across the world. Large numbers of manufacturers are focusing on the introduction of tracers capable of detecting beta-amyloid plaque density in patients with cognitive impairment who are being evaluated for Alzheimer’s disease.

Rise in Preference for PET/CT and PET Scans to Fuel PET Radiotracer Market Demand

PET scans could be used to evaluate organs and/or tissues for the presence of disease or other conditions. PET could also be used to evaluate the function of organs such as heart and brain. Detection of cancer and evaluation of cancer treatment are the common applications of PET, which has been recognized as a promising diagnostic tool to predict biological and physiological changes at the molecular level. Thus, PET offers a potential area for applications including stem cell research. The PET technique allows researchers to study the normal processes in the brain (central nervous system) of normal individuals and patients with neurologic illnesses without physical/structural damage to the brain. When a region of the brain is active, it uses more fuel in the form of oxygen and sugar (glucose). According to the American Nuclear Society, 90% of radioisotopes are used in gamma cameras or PET scan nuclear diagnostics. The remaining 10% are used in radioactive therapeutic drugs to treat diseases such as cancer and heart diseases, and gastrointestinal, endocrinal, and neurological disorders.

Request a custom report on PET Radiotracer Market

High Sensitivity in Detection of Seizure Foci Driving F-18 Segment

In terms of radiotracer type, the global market has been classified into F-18 (FDG18), Ga-68 (FAPI), and others. The F-18 (FDG18) segment dominated the global market in 2021, as FDG is the most commonly used radiotracer in clinical PET imaging. Different scientific research studies have stated that FDG PET has a sensitivity of more than 70% in detection of seizure foci as compared to other F-18 agents. This is driving the usage of FDG as a prominent PET drug tracer.

Rise in Usage of Radioisotopes in Oncology Propelling Cancer Segment

Based on radiotracer type, the global PET radiotracer market has been segregated into cancer, heart disease, gastrointestinal, endocrine, neurological disorders, and others. Most of the radioisotopes across the globe are used in oncology for diagnosis or radiation therapy. F-18 and Ga-68-based radioisotopes are primarily used in the diagnosis of cancer.

Availability of Advanced PET Systems and Trained Medical Personnel Augmenting Hospitals Segment

In terms of end-user, the hospitals segment dominated the global market for PET radiotracer in 2021. The trend is anticipated to continue during the forecast period. Increase in patient preference for hospitals for PET radiotracer diagnosis is expected to propel the hospitals segment during the forecast period. Furthermore, the hospitals segment is likely to grow at a high CAGR during the forecast period owing to the increase in number of neurology, cancer, and cardiac patients; availability of advanced PET systems at low cost; and presence of trained medical personnel.

Regional Outlook of Global PET Radiotracer Market

The U.S. and Europe, cumulatively, accounted for more than 95% market share for PET radiotracer in 2021. The U.S. was the dominant market in 2021. The trend is anticipated to continue during the forecast period. Growth of the market in the U.S. can be ascribed to the increase in usage of fluorine-18 for various diseases. According to the U.S. Centers for Disease Control, an estimated 2,096,000 clinical PET scans were performed in hospital and non-hospital sites using fixed PET imaging systems or mobile PET services in 2020.

Analysis of Key Players in Global PET Radiotracer Market

The report concludes with the company profiles section, which includes information about key players in the global PET radiotracer market. Key players are focusing on adopting strategies such as acquisition & collaboration, geographic expansion, expansion of distribution channels, and R&D to enhance their share in the global market. PET radiotracer companies analyzed in the report are ABX advanced biochemical compounds GmbH, Blue Earth Diagnostics, Cardinal Health, Eli Lilly and Company, GE Healthcare, IBA Radiopharma Solutions, Jubilant Pharma Limited, Lantheus Holdings, Inc., Siemens Healthineers AG, and Yantai Dongcheng Pharmaceutical Group Co., Ltd.

Key Developments in Global PET Radiotracer Market

  • In June 2021, IBA introduced its new high energy and high-capacity cyclotron, the Cyclone IKON, which offers the largest energy spectrum for PET and SPECT isotopes from 13 MeV to 30 MeV
  • On May 27, 2021, Lantheus Holdings, Inc. announced that the FDA had approved PYLARIFY, an F18-labeled PET imaging agent targeting prostate-specific membrane antigen (PSMA). PYLARIFY is a product in the radiopharmaceutical oncology product category. The company commercially launched PYLARIFY in the U.S. in June 2021.

Each of these players has been profiled in the PET radiotracer market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global PET Radiotracer Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 1.4 Bn

Market Forecast Value in 2031

More than US$ 3.2 Bn

Growth Rate (CAGR) for 2022-2031

8.5%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, the qualitative analysis includes PET radiotracer market drivers, restraints, opportunities, key trends, and a parent industry overview.

Competition Landscape

  • Market share analysis by the company (2021)
  • Company profiles section includes an overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Radiotracer Type
    • F-18 (FDG18)
    • Ga-68 (FAPI)
    • Others
  • Application
    • Cancer
    • Heart Disease
    • Gastrointestinal
    • Endocrine
    • Neurological Disorders
    • Others
  • End-user
    • Hospitals
    • Diagnostic Centers
    • Others

Regions Covered

  • U.S.
  • Europe
  • Rest of the World

Countries Covered

  • U.S.
  • Germany
  • U.K.
  • France
  • Italy
  • Spain

Companies Profiled

  • ABX advanced biochemical compounds GmbH (Cambridge Isotope Laboratories, Inc.)
  • Blue Earth Diagnostics
  • Cardinal Health
  • Eli Lilly and Company
  • GE Healthcare
  • IBA Radiopharma Solutions
  • Jubilant Pharma Limited
  • Lantheus Holdings, Inc.
  • Siemens Healthineers AG
  • Yantai Dongcheng Pharmaceutical Group Co., Ltd.

Customization Scope

Available upon request

Pricing

Available upon request

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global PET radiotracer market in 2021?

The global PET radiotracer market was valued at US$ 1.4 Bn in 2021.

How big will be the global PET radiotracer market in 2031?

The global PET radiotracer market is projected to reach more than US$ 3.2 Bn by 2031.

What was the CAGR of the global PET radiotracer market from 2017 to 2021?

The global PET radiotracer market grew at a CAGR of 3.9% from 2017 to 2021.

What will be the CAGR of the global PET radiotracer market during the forecast period (2022–2031)?

The global PET radiotracer market is anticipated to grow at a CAGR of 8.5% from 2022 to 2031.

What is the market share of the leading segment of the global PET radiotracer market?

The F-18 [FDG18] segment held more than 90% share of the global PET radiotracer market in 2021.

Which region will account for the major share of the global market during the forecast period?

The U.S. is expected to account for the major share of the global PET radiotracer market during the forecast period.

Who are the prominent players in the global PET radiotracer market?

ABX advanced biochemical compounds GmbH, Blue Earth Diagnostics, Cardinal Health, Eli Lilly and Company, GE Healthcare, IBA Radiopharma Solutions, Jubilant Pharma Limited, Lantheus Holdings Inc., Siemens Healthineers AG, and Yantai Dongcheng Pharmaceutical Group Co., Ltd.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global PET Radiotracer Market

4. Market Overview

    4.1. Introduction

        4.1.1. Radiotracer Type Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global PET Radiotracer Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Regulatory Scenario by Region/globally

    5.2. Key Industry Events (mergers, acquisitions, partnerships, etc.)

    5.3. Technological Advancements

    5.4. COVID 19 Impact Analysis

6. Global PET Radiotracer Market Analysis and Forecast, by Radiotracer Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Radiotracer Type, 2017–2031

        6.3.1. F-18 (FDG18)

        6.3.2. Ga-68 (FAPI)

        6.3.3. Others

    6.4. Market Attractiveness Analysis, by Radiotracer Type

7. Global PET Radiotracer Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Application, 2017–2031

        7.3.1. Cancer

        7.3.2. Heart Disease

        7.3.3. Gastrointestinal

        7.3.4. Endocrine

        7.3.5. Neurological Disorders

        7.3.6. Others

    7.4. Market Attractiveness Analysis, by Application

8. Global PET Radiotracer Market Analysis and Forecast, by End-user

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by End-user, 2017–2031

        8.3.1. Hospitals

        8.3.2. Diagnostic Centers

        8.3.3. Others

    8.4. Market Attractiveness Analysis, by End-user

9. Global PET Radiotracer Market Analysis and Forecast, by Country/Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Country/Region

        9.2.1. U.S.

        9.2.2. Europe

        9.2.3. Rest of the World

    9.3. Market Attractiveness Analysis, by Country/Region

10. U.S. PET Radiotracer Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Radiotracer Type, 2017–2031

        10.2.1. F-18 (FDG18)

        10.2.2. Ga-68 (FAPI)

        10.2.3. Others

    10.3. Market Value Forecast, by Application, 2017–2031

        10.3.1. Cancer

        10.3.2. Heart Disease

        10.3.3. Gastrointestinal

        10.3.4. Endocrine

        10.3.5. Neurological Disorders

        10.3.6. Others

    10.4. Market Value Forecast, by End-user, 2017–2031

        10.4.1. Hospitals

        10.4.2. Diagnostic Centers

        10.4.3. Others

    10.5. Market Attractiveness Analysis

        10.5.1. By Radiotracer Type

        10.5.2. By Application

        10.5.3. By End-user

11. Europe PET Radiotracer Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Radiotracer Type, 2017–2031

        11.2.1. F-18 (FDG18)

        11.2.2. Ga-68 (FAPI)

        11.2.3. Others

    11.3. Market Value Forecast, by Application, 2017–2031

        11.3.1. Cancer

        11.3.2. Heart Disease

        11.3.3. Gastrointestinal

        11.3.4. Endocrine

        11.3.5. Neurological Disorders

        11.3.6. Others

    11.4. Market Value Forecast, by End-user, 2017–2031

        11.4.1. Hospitals

        11.4.2. Diagnostic Centers

        11.4.3. Others

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Radiotracer Type

        11.6.2. By Application

        11.6.3. By End-user

        11.6.4. By Country/Sub-region

12. Rest of the World PET Radiotracer Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Radiotracer Type, 2017–2031

        12.2.1. F-18 (FDG18)

        12.2.2. Ga-68 (FAPI)

        12.2.3. Others

    12.3. Market Value Forecast, by Application, 2017–2031

        12.3.1. Cancer

        12.3.2. Heart Disease

        12.3.3. Gastrointestinal

        12.3.4. Endocrine

        12.3.5. Neurological Disorders

        12.3.6. Others

    12.4. Market Value Forecast, by End-user, 2017–2031

        12.4.1. Hospitals

        12.4.2. Diagnostic Centers

        12.4.3. Others

    12.5. Market Attractiveness Analysis

        12.5.1. By Radiotracer Type

        12.5.2. By Application

        12.5.3. By End-user

13. Competition Landscape

    13.1. Market Player – Competition Matrix (By Tier and Size of companies)

    13.2. Market Share Analysis By Company (2021)

    13.3. Company Profiles

        13.3.1. ABX advanced biochemical compounds GmbH

            13.3.1.1. Company Overview

            13.3.1.2. Strategic Overview

            13.3.1.3. SWOT Analysis

        13.3.2. Blue Earth Diagnostics

            13.3.2.1. Company Overview

            13.3.2.2. Financial Overview

            13.3.2.3. Strategic Overview

            13.3.2.4. SWOT Analysis

        13.3.3. Cardinal Health

            13.3.3.1. Company Overview

            13.3.3.2. Financial Overview

            13.3.3.3. Strategic Overview

            13.3.3.4. SWOT Analysis

        13.3.4. Eli Lilly and Company

            13.3.4.1. Company Overview

            13.3.4.2. Financial Overview

            13.3.4.3. Strategic Overview

            13.3.4.4. SWOT Analysis

        13.3.5. GE Healthcare

            13.3.5.1. Company Overview

            13.3.5.2. Financial Overview

            13.3.5.3. Strategic Overview

            13.3.5.4. SWOT Analysis

        13.3.6. IBA Radiopharma Solutions

            13.3.6.1. Company Overview

            13.3.6.2. Financial Overview

            13.3.6.3. Strategic Overview

            13.3.6.4. SWOT Analysis

        13.3.7. Jubilant Pharma Limited

            13.3.7.1. Company Overview

            13.3.7.2. Financial Overview

            13.3.7.3. Strategic Overview

            13.3.7.4. SWOT Analysis

        13.3.8. Lantheus Holdings, Inc.

            13.3.8.1. Company Overview

            13.3.8.2. Financial Overview

            13.3.8.3. Strategic Overview

            13.3.8.4. SWOT Analysis

        13.3.9. Siemens Healthineers AG

            13.3.9.1. Company Overview

            13.3.9.2. Financial Overview

            13.3.9.3. Strategic Overview

            13.3.9.4. SWOT Analysis

        13.3.10. Yantai Dongcheng Pharmaceutical Group Co., Ltd.

            13.3.10.1. Company Overview

            13.3.10.2. Financial Overview

            13.3.10.3. Strategic Overview

            13.3.10.4. SWOT Analysis

List of Tables

Table 01: Global PET Radiotracer Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031

Table 02: Global PET Radiotracer Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 03: Global PET Radiotracer Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 04: Global PET Radiotracer Market Value (US$ Mn) Forecast, by Country/Region, 2017–2031

Table 05: U.S. PET Radiotracer Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031

Table 06: U.S. PET Radiotracer Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 07: U.S. PET Radiotracer Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 08: Europe PET Radiotracer Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031

Table 09: Europe PET Radiotracer Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 10: Europe PET Radiotracer Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 11: Europe PET Radiotracer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 12: Rest of the World PET Radiotracer Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031

Table 13: Rest of the World PET Radiotracer Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 14: Rest of the World PET Radiotracer Market Value (US$ Mn) Forecast, by End-user, 2017–2031

List of Figures

Figure 01: Global PET Radiotracer Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 02: Global PET Radiotracer Market Value Share Analysis, by Radiotracer Type, 2021 and 2031

Figure 03: Global PET Radiotracer Market Attractiveness Analysis, by Radiotracer Type, 2022–2031

Figure 04: Global PET Radiotracer Market Value (US$ Mn) Forecast, by F-18 (FDG18), 2017–2031

Figure 05: Global PET Radiotracer Market Value (US$ Mn) Forecast, by Ga-68 (FAPI), 2017–2031

Figure 06: Global PET Radiotracer Market Value (US$ Mn) Forecast, by Others, 2017–2031

Figure 07: Global PET Radiotracer Market Value Share Analysis, by Application, 2021 and 2031

Figure 08: Global PET Radiotracer Market Attractiveness Analysis, by Application, 2022–2031

Figure 09: Global PET Radiotracer Market Value (US$ Mn) Forecast, by Cancer, 2017–2031

Figure 10: Global PET Radiotracer Market Value (US$ Mn) Forecast, by Heart Disease, 2017–2031

Figure 11: Global PET Radiotracer Market Value (US$ Mn) Forecast, by Gastrointestinal, 2017–2031

Figure 12: Global PET Radiotracer Market Value (US$ Mn) Forecast, by Endocrine, 2017–2031

Figure 13: Global PET Radiotracer Market Value (US$ Mn) Forecast, by Neurological Disorders, 2017–2031

Figure 14: Global PET Radiotracer Market Value (US$ Mn) Forecast, by Others, 2017–2031

Figure 15: Global PET Radiotracer Market Value Share Analysis, by End-user, 2021 and 2031

Figure 16: Global PET Radiotracer Market Attractiveness Analysis, by End-user, 2022–2031

Figure 17: Global PET Radiotracer Market Value (US$ Mn) Forecast, by Hospitals, 2017–2031

Figure 18: Global PET Radiotracer Market Value (US$ Mn) Forecast, by Diagnostic Centers, 2017–2031

Figure 19: Global PET Radiotracer Market Value (US$ Mn) Forecast, by Others, 2017–2031

Figure 20: Global PET Radiotracer Market Value Share Analysis, by Country/Region, 2021 and 2031

Figure 21: Global PET Radiotracer Market Attractiveness Analysis, by Country/Region, 2022–2031

Figure 22: U.S. PET Radiotracer Market Value (US$ Mn) Forecast, 2017–2031

Figure 23: U.S. PET Radiotracer Market Value Share Analysis, by Radiotracer Type, 2021 and 2031

Figure 24: U.S. PET Radiotracer Market Attractiveness Analysis, by Radiotracer Type, 2022–2031

Figure 25: U.S. PET Radiotracer Market Value Share Analysis, by Application, 2021 and 2031

Figure 26: U.S. PET Radiotracer Market Attractiveness Analysis, by Application, 2022–2031

Figure 27: U.S. PET Radiotracer Market Value Share Analysis, by End-user, 2021 and 2031

Figure 28: U.S. PET Radiotracer Market Attractiveness Analysis, by End-user, 2022–2031

Figure 29: Europe PET Radiotracer Market Value (US$ Mn) Forecast, 2017–2031

Figure 30: Europe PET Radiotracer Market Value Share Analysis, by Radiotracer Type, 2021 and 2031

Figure 31: Europe PET Radiotracer Market Attractiveness Analysis, by Radiotracer Type, 2022–2031

Figure 32: Europe PET Radiotracer Market Value Share Analysis, by Application, 2021 and 2031

Figure 33: Europe PET Radiotracer Market Attractiveness Analysis, by Application, 2022–2031

Figure 34: Europe PET Radiotracer Market Value Share Analysis, by End-user, 2021 and 2031

Figure 35: Europe PET Radiotracer Market Attractiveness Analysis, by End-user, 2022–2031

Figure 36: Europe PET Radiotracer Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 37: Europe PET Radiotracer Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 38: Rest of the World PET Radiotracer Market Value (US$ Mn) Forecast, 2017–2031

Figure 39: Rest of the World PET Radiotracer Market Value Share Analysis, by Radiotracer Type, 2021 and 2031

Figure 40: Rest of the World PET Radiotracer Market Attractiveness Analysis, by Radiotracer Type, 2022–2031

Figure 41: Rest of the World PET Radiotracer Market Value Share Analysis, by Application, 2021 and 2031

Figure 42: Rest of the World PET Radiotracer Market Attractiveness Analysis, by Application, 2022–2031

Figure 43: Rest of the World PET Radiotracer Market Value Share Analysis, by End-user, 2021 and 2031

Figure 44: Rest of the World PET Radiotracer Market Attractiveness Analysis, by End-user, 2022–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

813

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved